Please assess the completion status of the following clinical trial:

Trial Title: A Study of Herceptin (Trastuzumab) in Patients With Metastatic or Advanced Gastric Cancer With Disease Progression

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* adult patients 18-75 years of age;~* metastatic or advanced gastric cancer;~* disease progression under or after 1 prior platinum-based or 5-fluoropyrimidine-based chemotherapy for metastatic disease;~* \>=4 weeks from last platinum-based or fluoropyrimidine-based chemotherapy;~* \>=1 measurable lesion;~* HER2 overexpression (IHC \[2+\] or \[3+\]).~Exclusion Criteria:~* concurrent chemotherapy or immunotherapy;~* brain or meningeal metastases;~* clinically significant cardiac disease, advanced pulmonary disease or severe dyspnoea;~* co-existing malignancies or malignancies diagnosed within last 5 years, except basal cell cancer or cervical cancer in situ;~* women who are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Trastuzumab Monotherapy (Type: EXPERIMENTAL): Initial dose of 4 milligrams (mg) per (/) kilogram (kg) by body weight (BW), followed by 2 mg/kg BW at each subsequent visit

Based on this trial design, predict the completion outcome and termination type (if applicable).